LiHY,TanakaK,OeserB,WertmanB,KobashigawaJA,TobisJMCompensatoryenlargementintransplantcoronaryarterydisease:ChinMedJ(Engl)2006Apr5;119(7):564-LiH,TanakaK,AnzaiH,OeserB,LaiD,KobashigawaJA,TobisJMInfluenceofpre-JAmCollC2006;47(12):2470-LiH,TanakaK,OeserB,KobashigawaJA,TobisJMVascularremodellingaftercardiactransplantation:a3-EurHeartJ2006;27(14):1671-LiH,TanakaK,ChhabraA,OeserB,KobashigawaJA,TobisJMVascularRemodeling1YearAfterCardiacTJHeartLungT2007;26(1):56-何榕,杨振华,李海燕*,郭丽君,张福春,牛杰,张永珍,王贵松,高炜。急诊经皮冠状动脉介入治疗术后中性粒细胞升高与预后的相关性。中华心血管病杂志,2009;37(1):44-48。何榕,杨振华,李海燕*,郭丽君,张福春,牛杰,张永珍,王贵松,高炜。急诊冠状动脉介入治疗术后纤维蛋白原和C反应蛋白水平联合预测患者预后。中国介入心脏病学杂志,2009,17(1):34-38。(通讯作者:李海燕)佘飞、李海燕*。药物心脏安全性评估与全面QT/QTc研究。中国临床药理学杂志,2011;27(3)::22-李海燕,吉萍。《药物临床试验质量管理规范》(GCP)在临床研究中的价值及我国研究者的依从情况。北京大学学报(医学版),2010;42:637-HERong,LIHai-yan*,GUOLi-jun,ZHANGFu-chun,NIUJie,ZHANGYong-zhen,WANGGui-song,YANGZhen-huaandGAOWPredictivevalueofpostproceduralleukocytecountonmyocardialperfusion,leftventricularfunctionandclinicaloutcomesinST-ChineseMedicalJ2012;125(6):1023-张晓方,李海燕*,姚晨,王燕芳。搭建培训平台传播先进理念以提高我国新药研发创新能力。中国新药杂志,2012;21(12):1318-1321。郭京川,李海燕*。创新药的心脏安全性评价与全面QT研究。中国药学杂志,2012;47(15):1185-LiH,YangL,TouCK,PatelCG,ZhaoJPharmacokineticstudyofsaxagliptininhealthyCClinDrugI2012;32(7):465-HaiyanLi,KathleenButler,LiYang,ZhenghuaYangandRenliTPharmacokineticsandTolerabilityofSingleandMultipleDosesofTicagrelorinHealthyChineseSClinDrugInvestig2012;32(2):87-LILei,LIHai-yan*,QIAORui,YUHai-yi,ZENGHui,GAOWei,ZHANGJPChineseMedicalJournal2013;126(4):626-吉萍;李海燕*。临床研究的伦理规范。中华肾病研究电子杂志,2014;3(1):10-13